Atopiclair regulatory update

SPH received Australian marketing approval for Atopiclair as a class IIa medical device to treat atopic dermatitis (eczema). Intendis GmbH, a unit of Bayer AG (FSE:BAY; BAY, Leverkusen, Germany), co-...